Should I buy or sell CymaBay Therapeutics stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CBAY shares. View CBAY analyst ratings or view top-rated stocks .

What is CymaBay Therapeutics' stock price target for 2024?

12 analysts have issued 12-month target prices for CymaBay Therapeutics' stock. Their CBAY share price targets range from $12.00 to $34.00. On average, they expect the company's stock price to reach $22.27 in the next twelve months. This suggests a possible upside of 9.1% from the stock's current price. View analysts price targets for CBAY or view top-rated stocks among Wall Street analysts .

How have CBAY shares performed in 2023?

CymaBay Therapeutics' stock was trading at $6.27 at the start of the year. Since then, CBAY shares have increased by 225.7% and is now trading at $20.42. View the best growth stocks for 2023 here .

Are investors shorting CymaBay Therapeutics?

CymaBay Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 11,910,000 shares, an increase of 9.1% from the October 31st total of 10,920,000 shares. Based on an average daily volume of 2,260,000 shares, the short-interest ratio is currently 5.3 days. View CymaBay Therapeutics' Short Interest .

When is CymaBay Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our CBAY earnings forecast .

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) posted its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.02. During the same period in the previous year, the business posted ($0.28) earnings per share.

What ETFs hold CymaBay Therapeutics' stock?

ETFs with the largest weight of CymaBay Therapeutics (NASDAQ:CBAY) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) , SPDR S&P Pharmaceuticals ETF (XPH) , AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and ALPS Medical Breakthroughs ETF (SBIO) . iShares Micro-Cap ETF (IWC) .

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , OPKO Health (OPK) , Pfizer (PFE) , Alibaba Group (BABA) , Novavax (NVAX) , Corbus Pharmaceuticals (CRBP) , Energy Transfer (ET) and Viking Therapeutics (VKTX) .

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (6.12%), Adage Capital Partners GP L.L.C. (3.64%), Jennison Associates LLC (3.22%), Fred Alger Management LLC (1.92%), FMR LLC (1.38%) and Affinity Asset Advisors LLC (1.00%). Insiders that own company stock include Charles Mcwherter, Daniel Menold, Dennis D Kim , Kurt Von Emster, Paul T Quinlan and Sujal Shah. View institutional ownership trends .

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

CymaBay Therapeutics Stock Price, News & Analysis (NASDAQ:CBAY)

$20.49

+0.07 (+0.34%)

(As of 10:04 AM ET)

Compare

Today's Range: $20.23
▼
$20.76
50-Day Range: $12.63
▼
$20.42
52-Week Range: $3.83
▼
$21.06

Volume: 74,205 shs
Average Volume: 1.90 million shs
Market Capitalization: $2.32 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $22.27

CymaBay Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.08 Rating Score
Upside/Downside: 9.1% Upside
$22.27 Price Target
Short Interest: Bearish
10.50% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.88
Upright™ Environmental Score
News Sentiment: -0.01
Based on 2 Articles This Week
Insider Trading: Selling Shares
$3.09 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.94) to ($1.33) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

804th out of 949 stocks

Pharmaceutical Preparations Industry

365th out of 421 stocks

2.5

Analyst's Opinion

Consensus Rating
CymaBay Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 11 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $22.27, CymaBay Therapeutics has a forecasted upside of 9.1% from its current price of $20.42.
Amount of Analyst Coverage
CymaBay Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
10.50% of the outstanding shares of CymaBay Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
CymaBay Therapeutics has a short interest ratio ("days to cover") of 5.3.
Change versus previous month
Short interest in CymaBay Therapeutics has recently increased by 9.07%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
CymaBay Therapeutics does not currently pay a dividend.
Dividend Growth
CymaBay Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
CymaBay Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for CymaBay Therapeutics is -0.88.

1.1

News and Social Media Coverage

News Sentiment
CymaBay Therapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for CymaBay Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 6 people have searched for CBAY on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.
MarketBeat Follows
Only 12 people have added CymaBay Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CymaBay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,086,453.00 in company stock.
Percentage Held by Insiders
Only 7.00% of the stock of CymaBay Therapeutics is held by insiders.
Percentage Held by Institutions
95.03% of the stock of CymaBay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for CymaBay Therapeutics are expected to decrease in the coming year, from ($0.94) to ($1.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CymaBay Therapeutics is -22.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CymaBay Therapeutics is -22.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CymaBay Therapeutics has a P/B Ratio of 47.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About CymaBay Therapeutics Stock (NASDAQ:CBAY)

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

CBAY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CBAY Stock News Headlines

December 5, 2023 | americanbankingnews.com

Short Interest in CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Increases By 9.1%

December 2, 2023 | americanbankingnews.com

CymaBay Therapeutics (NASDAQ:CBAY) Hits New 1-Year High at $19.79

December 6, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 26, 2023 | americanbankingnews.com

CymaBay Therapeutics (NASDAQ:CBAY) Trading 5.3% Higher

November 24, 2023 | seekingalpha.com

CBAY CymaBay Therapeutics, Inc.

November 19, 2023 | seekingalpha.com

Circling Back On CymaBay Therapeutics

November 18, 2023 | finance.yahoo.com

Insider Sell Alert: President of R&D Charles Mcwherter Sells 11,342 Shares of CymaBay ...

November 16, 2023 | finance.yahoo.com

Insider Sell Alert: CEO Sujal Shah Divests 64,863 Shares of CymaBay Therapeutics Inc

December 6, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 15, 2023 | markets.businessinsider.com

Superior Efficacy, Safety, and Benefits of Seladelpar Boosts CymaBay Therapeutics’ Rating: Julian Harrison’s Analysis

November 15, 2023 | markets.businessinsider.com

Promising Outlook for CymaBay Therapeutics: Superior Efficacy of Seladelpar in PBC Treatment Justifies Buy Rating

November 15, 2023 | markets.businessinsider.com

Promising Phase III Study Results Boost CymaBay’s Market Potential Amid Competitor Safety Concerns

November 14, 2023 | bizjournals.com

East Bay company's 'greatest biotech comeback' drives toward drug approval in rare liver disease

November 13, 2023 | finance.yahoo.com

CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting®

November 10, 2023 | markets.businessinsider.com

Promising Developments in CymaBay Therapeutics’ Seladelpar Program Drive ‘Buy’ Rating

November 9, 2023 | morningstar.com

CymaBay Therapeutics Inc CBAY

November 9, 2023 | finance.yahoo.com

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q3 2023 Earnings Call Transcript

November 8, 2023 | benzinga.com

Recap: CymaBay Therapeutics Q3 Earnings

November 8, 2023 | markets.businessinsider.com

Raymond James Maintains Strong Buy Rating for CymaBay Therapeutics: Here's What You Need To Know

November 8, 2023 | finance.yahoo.com

Does CymaBay Therapeutics Inc. (CBAY) Have the Potential to Rally 45.99% as Wall Street Analysts Expect?

November 7, 2023 | finance.yahoo.com

CymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate Update

November 6, 2023 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on CymaBay Therapeutics (CBAY)

November 6, 2023 | markets.businessinsider.com

Where CymaBay Therapeutics Stands With Analysts

November 1, 2023 | finance.yahoo.com

CymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis

October 31, 2023 | finance.yahoo.com

CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023

October 26, 2023 | markets.businessinsider.com

FDA’s Breakthrough Therapy Designation Expansion Bolsters CymaBay Therapeutics’ Buy Rating

October 23, 2023 | finance.yahoo.com

CymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023

See More Headlines

Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CBAY
CUSIP: N/A
CIK: 1042074
Web: www.cymabay.com
Phone: (510) 293-8800
Fax: 510-293-9090
Employees: 60
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $22.27
High Stock Price Target: $34.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +9.1%
Consensus Rating: Buy
Rating Score (0-4): 3.08
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-106,000,000.00
Net Margins: N/A
Pretax Margin: -290.50%
Return on Equity: -62.69%
Return on Assets: -33.85%

Debt

Debt-to-Equity Ratio: 0.32
Current Ratio: 22.76
Quick Ratio: 22.76

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.43 per share
Price / Book: 47.49

Miscellaneous

Outstanding Shares: 113,400,000
Free Float: 105,465,000
Market Cap: $2.32 billion
Optionable: Optionable
Beta: 0.34

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Sujal A. Shah (Age 50)
President, CEO & Director
Comp: $1.04M
Dr. Charles A. McWherter Ph.D. (Age 68)
President of Research & Development and Chief Scientific Officer
Comp: $700.65k
Mr. Paul T. Quinlan (Age 60)
General Counsel, Chief Compliance Officer & Corporate Secretary
Comp: $629.72k
Mr. Harish Shantharam C.F.A.
Chief Financial Officer
Mr. Ken Boehm
Senior Vice President of Human Resources
Mr. Patrick J. O'Mara (Age 62)
Senior Vice President of Business Development
Dr. Robert L. Martin (Age 61)
Senior Vice President of Manufacturing & Nonclinical Development
Ms. Klara A. Dickinson-Eason (Age 55)
Chief Regulatory & Quality Assurance Officer
Comp: $441.84k
Ms. Becki Filice (Age 62)
Senior Vice President of Portfolio & Product Leadership
Mr. Lewis J. Stuart B.A. (Age 64)
M.B.A., Chief Commercial Officer
Comp: $378.79k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CBAY Stock Analysis - Frequently Asked Questions

Should I buy or sell CymaBay Therapeutics stock right now?: 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CBAY shares.
View CBAY analyst ratings or view top-rated stocks.
What is CymaBay Therapeutics' stock price target for 2024?: 12 analysts have issued 12-month target prices for CymaBay Therapeutics' stock. Their CBAY share price targets range from $12.00 to $34.00. On average, they expect the company's stock price to reach $22.27 in the next twelve months. This suggests a possible upside of 9.1% from the stock's current price.
View analysts price targets for CBAY or view top-rated stocks among Wall Street analysts.
How have CBAY shares performed in 2023?: CymaBay Therapeutics' stock was trading at $6.27 at the start of the year. Since then, CBAY shares have increased by 225.7% and is now trading at $20.42.
View the best growth stocks for 2023 here.
Are investors shorting CymaBay Therapeutics?: CymaBay Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 11,910,000 shares, an increase of 9.1% from the October 31st total of 10,920,000 shares. Based on an average daily volume of 2,260,000 shares, the short-interest ratio is currently 5.3 days.
View CymaBay Therapeutics' Short Interest.
When is CymaBay Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our CBAY earnings forecast.
How were CymaBay Therapeutics' earnings last quarter?: CymaBay Therapeutics, Inc. (NASDAQ:CBAY) posted its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.02. During the same period in the previous year, the business posted ($0.28) earnings per share.

What ETFs hold CymaBay Therapeutics' stock?: ETFs with the largest weight of CymaBay Therapeutics (NASDAQ:CBAY) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), SPDR S&P Pharmaceuticals ETF (XPH), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and ALPS Medical Breakthroughs ETF (SBIO).iShares Micro-Cap ETF (IWC).
What other stocks do shareholders of CymaBay Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).
Who are CymaBay Therapeutics' major shareholders?: CymaBay Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (6.12%), Adage Capital Partners GP L.L.C. (3.64%), Jennison Associates LLC (3.22%), Fred Alger Management LLC (1.92%), FMR LLC (1.38%) and Affinity Asset Advisors LLC (1.00%). Insiders that own company stock include Charles Mcwherter, Daniel Menold, Dennis D Kim, Kurt Von Emster, Paul T Quinlan and Sujal Shah.
View institutional ownership trends.
How do I buy shares of CymaBay Therapeutics?: Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CBAY) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

CymaBay Therapeutics Stock Price, News & Analysis (NASDAQ:CBAY)

CymaBay Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About CymaBay Therapeutics Stock (NASDAQ:CBAY)

CBAY Stock Price History

CBAY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CBAY Stock Analysis - Frequently Asked Questions

Overall MarketRank^™